Withings presents its new smart scale as a longevity station

Withings unveiled the Body Scan 2 at CES 2026, a $599.95 smart scale that performs a 90‑second assessment and tracks more than 60 biomarkers. The company says two features will seek FDA clearance and the device is planned for release in Q2 2026.

Withings showed the Body Scan 2 smart scale at CES 2026 and is positioning it as a small at-home "longevity station." The platform includes eight electrodes in the scale and a retractable handle with four more electrodes to include upper-body data. The device runs a roughly 90‑second assessment that the company says covers more than 60 biomarkers and produces a single Health Trajectory score. Withings emphasizes noninvasive measurements and regular use as the reason to consolidate many metrics into a familiar device. Key features: - Hardware includes eight foot electrodes plus a retractable handle with four electrodes to capture both lower- and upper-body signals. - The Body Scan 2 conducts a roughly 90‑second “longevity assessment” covering over 60 biomarkers grouped around heart pumping and electrical activity, hypertension risk, artery health, cellular/metabolic efficiency, and glycemic regulation. - Noninvasive metabolic measurements reported by the company include bioimpedance spectroscopy (BIS) and a sweat-gland response measured from the feet. - The app produces a Health Trajectory score to visualize healthspan and also stores the full set of biomarkers for review; an Eyes-Closed Mode can hide numeric readouts on the scale itself. - Two features — hypertension risk notifications and a six-lead ECG for atrial fibrillation detection — will require FDA clearance, and Withings plans GDPR and HIPAA compliance plus ISO 27001 and ISO 27701 certifications; the company aims for a Q2 2026 availability. Summary: The Body Scan 2 bundles multiple clinical-style sensors into a consumer scale to provide frequent, broad measurements of cardiovascular and metabolic markers. The immediate impact is broader at-home monitoring and a consolidated Health Trajectory score; regulatory review for specific features and planned certifications are the next stated steps toward a Q2 2026 launch.